The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report

Parkinson's disease is characterized by the loss of nigrostriatal dopaminergic neurons in the brain. Dopamine cannot be administered systemically because it does not cross the blood-brain barrier. Oral levodopa remains the gold standard to date. Currently, for patients who show a poor response...

Descripción completa

Detalles Bibliográficos
Autores principales: Thirunavukarasu, Suresh, Ramanan, Balasubramanian Bala Venkata, Suresh, Sathya Krishnan, Antonisamy, Vincent Jayakumar, Varadharaj, Devi, Shanmugam, Paranjothi, Verma, Kavita, Elumalai, Canmany, Selvakumar, Gladson, Elumalai, Ahila, Prabahar, Lydia, Janardhanan, Hridwik Adiyeri, UR, Anoop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687491/
https://www.ncbi.nlm.nih.gov/pubmed/38034171
http://dx.doi.org/10.7759/cureus.48011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687491/
https://www.ncbi.nlm.nih.gov/pubmed/38034171
http://dx.doi.org/10.7759/cureus.48011

Ejemplares similares